New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
06:20 EDTBCRXBioCryst BSAV BCX4430 highly effective agaist yellow fever in preclinical model
BioCryst Pharmaceuticals announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against yellow fever virus infection. BCX4430 is the lead compound in BioCryst's broad-spectrum antiviral, or BSAV, research program. The objective of BioCryst's BSAV program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to national health and security.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2014
07:21 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
Subscribe for More Information
August 12, 2014
07:15 EDTBCRXWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
August 8, 2014
10:00 EDTBCRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:33 EDTBCRXBioCryst initiated with an Overweight at JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use